Drug Profile
SC 10914
Alternative Names: SC10914Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Shanghai De Novo Pharmatech
- Developer Jiangxi Qingfeng Pharmaceutical; Shanghai De Novo Pharmatech
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Ovarian cancer
- No development reported Solid tumours
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (PO)
- 15 Dec 2020 Phase-II clinical trials in Ovarian cancer (Late-stage disease, Monotherapy, Second-line therapy or greater) in China (PO) (NCT04556539)
- 21 Sep 2020 Jiangxi Qingfeng Pharmaceutical plans a phase II trial for Ovarian cancer, Fallopian tube cancer and Peritoneal cancer (Second-line therapy or greater, Monotherapy, Late-stage disease) in China in September 2020 (PO, Tablet) (NCT04556539)